PIK3CA and neoplasm: This means new treatments can be tested on these non-responsive tumours in vitro like non-cisplatin compounds, including inhibitors of the PI3K/AKT/mTOR pathway, Poly(ADP-Ribose) Polymerase 1 (PARP), the tyrosine kinase, Wee1 and gemcitabine.